Gisadenafil (UK-369003) is a specific, orally activephosphodiesterase5 (PDE5)inhibitor with anIC₅₀of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP)^[1].

Since some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed. This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. TheIC₅₀of Gisadenafil for PDE5A is 3.6 nM. In contrast, theIC₅₀of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity^[1].

Gisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels^[1].

519.62

C₂₃H₃₃N₇O₅S

334826-98-1

吉沙那非

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.